The HMGN5 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population generated from the HT29 colorectal adenocarcinoma cell line, engineered to disrupt the HMGN5 gene. This polyclonal pool provides a heterogeneous loss-of-function model for studying HMGN5-dependent biological processes without clonal selection biases. The product is supplied as a ready-to-use polyclonal cell population, facilitating immediate application in cancer research.
The HT29 cell line is a well-characterized model of human colorectal adenocarcinoma, originally derived from a female patient. These cells exhibit epithelial morphology and retain key features of intestinal epithelial cells, including activation of the Wnt/??-catenin pathway due to an APC mutation. HT29 cells are widely employed in colorectal cancer research to investigate tumor cell proliferation, differentiation, and drug responsiveness.
HMGN5 encodes a nucleosome-binding protein that regulates chromatin accessibility and transcription. It is implicated in the activation of oncogenic transcriptional programs, particularly through interactions with nucleosomes and components of the SWI/SNF chromatin remodeling complex. HMGN5 is positively regulated by Wnt/??-catenin signaling via TCF/LEF transcription factors and is also under the control of c-Myc, E2F1, and p53. Downstream, HMGN5 promotes the expression of critical effectors such as c-Myc, cyclin D1, MMP9, survivin, and Bcl-2, thereby driving cell cycle progression, survival, and migration. Its deletion in HT29 cells is expected to impair the transcription of these targets, thereby attenuating Wnt/??-catenin and MAPK/ERK pathway outputs.
In the HT29 colorectal cancer context, HMGN5 knockout disrupts the chromatin-mediated regulation of oncogene expression, providing a powerful tool to dissect the epigenetic mechanisms underlying colorectal tumorigenesis. The loss of HMGN5 is predicted to compromise the proliferative and migratory capacity of these cells, as well as their anchorage-independent growth, making this model particularly valuable for studying tumor aggressiveness and metastatic potential. Moreover, the interplay between HMGN5 and DNA damage response pathways suggests utility in examining genomic instability in cancer.
This knockout cell model is suitable for a broad range of experimental approaches, including Western blot and RT-qPCR for target gene validation, proliferation assays (MTS, BrdU), migration and invasion assays (wound healing, Transwell), colony formation assays, and flow cytometric analysis of cell cycle distribution. Researchers can employ RNA-seq and ChIP-qPCR to map HMGN5-dependent transcriptional and chromatin changes. Additionally, the cells can be used in reporter assays for Wnt/??-catenin activity and in drug sensitivity screens to identify compounds that selectively target HMGN5-deficient tumors. For further information or technical support, please contact Ascent Research.
